Abstract:Advanced therapy medicinal products (ATMPs) are rapidly evolving to offer new treatment options. The scientific, technical, and clinical complexities subject drug regulatory authorizes to regulatory challenges. To advance the regulatory capacity for ATMPs, the National Medical Products Administration in China made changes to the drug regulatory system and developed regulatory science with the goal of addressing patient needs and encouraging innovation. This study aimed to systematically identify the regulatory evidence on ATMPs in China under the guidance of an overarching framework from the World Health Organization Global Benchmarking Tool. It was found that China's administrative authorities at all levels have issued a number of policy documents to promote the development of ATMPs, covering biopharmaceutical products research and development (n = 14), biopharmaceutical industry development (n = 9), high-quality development of medical institutions (n = 1), specific development plans/projects (n = 6) and specific regional development (n = 4). The legal and regulatory framework of ATMPs in China has been established and is subject to continuous adjustment in various aspects including regulations (n = 3), departmental rules or administrative normative documents (n = 22), and technical guidance (n = 15). As the regulatory reform continues, the drug review processes have been revised, and various technical standards have been launched, which aim to establish a regulatory approach that oversees the full life-cycle development of ATMPs in the country. The limited number of investigational new drug applications and approved ATMPs suggests a lag remains between the translation of advanced therapeutic technologies into clinically available medical products. To accelerate the translational research of ATMP in countries such as China, developing and adopting real-world evidence generated from clinical use in designated healthcare facilities to support scientific decision-making in ATMP regulation is warranted. The enhancement of regulatory capacity building and multi-stakeholder collaborations should also be encouraged to facilitate the timely evaluation of promising ATMPs to meet more patient needs.

Data protection provisions for biologics in TPP and policy orientation in China

Legal Protection of China's Biotechnology Patents

Analysis of the Legislative Evolution and Causes of Biologics Data Protection System in the United States

Comparative Study on Pharmaceutical Data Protection System of China and Japan

Setting Method Study of Data Protection Period for Biologics——Based on the Comparative Analysis of American and Japanese Methods

TRIPS-plus and Access to Medicines in China.

Discussion on Legal Basis of Drug Data Protection System

Rethinking Test Data Protection in China-US Trade War: Integrating Empirical and Normative Analysis

Introduction and Profound Consideration on Intellectual Property Rights Protection Standard Terms Relat-ed to Drugs beyond the Regulations of TRIPS

Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad

Policy selection of regulatory data protection under the background of drug innovation strategy in China

Study on the positive effects of data protection system on the availability of innovative drug--based on a comparative analysis of keppra marketing between China and America

Pharmaceutical corporate power, traditional medical knowledge, and intellectual property governance in China

Impact of medical data protection on drug expenditure and accessibility in China

On the Legal Supervision of Transgenic Animal Bioreactor Pharmacy in China

Considerations about Modification of Laws and Rules on Boosting Transgenic Research and Industrialization in China

The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards

Assessing Legal Protection of Biometric Data in China: Gaps, Principles, and Policy Recommendations

Evolution and Governance of the Biopharmaceutical Industrial Technology of China

Status Quo and Development Proposals of Biopharmaceutical Industry in China

Analysis on TRIPS-Plus Obligations of the TPP IP Clauses